MIAMI--(BUSINESS WIRE)--A major scientific breakthrough in the development of novel cancer therapeutics targeting the Notch pathway has been published online ahead of print in the journal Cancer Research.
MIAMI--(BUSINESS WIRE)--A major scientific breakthrough in the development of novel cancer therapeutics targeting the Notch pathway has been published online ahead of print in the journal Cancer Research.
Even as the debate rages on, the International Society for Stem Cell Research (ISSCR) is expected to come up with revised guidelines for stem-cell research involving chimaeras.
The FDA approval of idecabtagene vicleucel (ide-cel; Abecma) has established a role for CAR T-cell therapy in heavily pretreated, relapsed/refractory multiple myeloma, with the product showing an unprecedented response rate and a generally favorable safety profile, said Saad Z. Usmani, MD, FACP. However, with additional BCMA-directed constructs, allogeneic CAR T-cell products, and bispecific antibodies in the pipeline, ide-cel could become just 1 of many novel options the field.
Treatment options for chronic myeloid leukemia often include targeted therapies. Treatment plans and their effectiveness may depend on the phase of the condition. Chronic myeloid leukemia (CML) is a slow-growing type of blood cancer that can affect white and red blood cells and platelets.
In response to emailed questions, Cellino Biotech CEO and Co-founder Dr. Nabiha Saklayen, talked about the formation of the company and its goal to make stem cell therapies more accessible for patients
Dublin, April 13, 2021 (GLOBE NEWSWIRE) -- The "Global Induced Pluripotent Stem Cell (iPS Cell) Industry Report 2021" report has been added to ResearchAndMarkets.com's offering.
When it comes to Alzheimers versus science, science is on the losing side. Alzheimers is cruel in the most insidious way.
Guelph, ON, Canada April 12, 2021 eQcell Inc. Canadas premier clinical-stage regenerative medicine company addressing conditions and diseases affecting sporting and domestic animals globally, announces the appointment to its Board of Directors of Mr.
Photo Submitted Left: Jorge Almodovar, Right: Raj Rao Two U of A researchers received a $480,000 National Science Foundation grant to investigate how engineered coatings that imitate the tissue matrixsurroundingcells would affect the behavior of therapeutic human mesenchymal stromal cells, or hMSCs. Jorge Almodovar, assistant professor of chemical engineering, and Raj Rao, professor and head of the Department of Biomedical Engineering, were awarded the grant from the NSF Division of Chemical, Bioengineering, Environmental, and Transport Systems. The grant will support research to explore how the extracellular matrix mimetic coatings affect the behavior of therapeutic hMSCs
2021 marks the 20th anniversary of Lonzas groundbreaking Nucleofector Technology, the industrys leading non-viral cell transfection method, which has been cited more than 10,000 times, including in research by two Nobel Laureates. The innovative Nucleofector Technology enables the transfer of nucleic acids and proteins directly into the cells nuclei by combining optimized electrical parameters and cell type-specific solutions.
Recent Comments